Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: The development of increasingly sophisticated preclinical models over the recent years has provided the platform from which to rationally develop molecular targeted therapies for both NF1 and NF2-related tumors, such as within the Department of Defense-sponsored Neurofibromatosis Clinical Trials Consortium. SUMMARY:
|
Authors | Matthias A Karajannis, Rosalie E Ferner |
Journal | Current opinion in pediatrics
(Curr Opin Pediatr)
Vol. 27
Issue 1
Pg. 26-33
(Feb 2015)
ISSN: 1531-698X [Electronic] United States |
PMID | 25490687
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antineoplastic Agents
- Neurofibromin 1
- Neurofibromin 2
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Child
- Child, Preschool
- Clinical Trials as Topic
- Gene Expression Regulation, Neoplastic
- Genetic Predisposition to Disease
- Humans
- Infant
- Magnetic Resonance Imaging
- Molecular Targeted Therapy
(trends)
- Nerve Sheath Neoplasms
(genetics, pathology, therapy)
- Neurofibromatosis 1
(genetics, pathology, therapy)
- Neurofibromatosis 2
(genetics, pathology, therapy)
- Neurofibromin 1
(genetics, metabolism)
- Neurofibromin 2
(genetics)
- Peripheral Nervous System Neoplasms
(genetics, pathology, therapy)
- Skin Neoplasms
(genetics, pathology, therapy)
|